tbuckley/cabot-search huggingface dataset:
Retinol-Binding Protein-Dependent Cholesterol Uptake Regulates Macrophage Foam Cell Formation and Promotes Atherosclerosis
Authors: Yan Liu, Yuan Zhong, Hongen Chen, Duan Wang, Min Wang, Jing-Song Ou, Min Xia
Journal: Circulation (2017)

Background: Retinol-binding protein 4 (RBP4) is an adipokine that plays decisive roles in glucose metabolism and insulin sensitivity. Elevated circulating RBP4 levels were reported to be associated with increased risk for cardiovascular disease, but the precise role of RBP4 in atherosclerotic diseases and its mechanisms of action remain elusive. Methods: Serum RBP4 levels of 1683 participants from South China were evaluated and the occurrence of major adverse cardiovascular events was followed up for 5 years. Apolipoprotein E-deficient mice infected with RBP4-overexpressing/silencing adenovirus, J774A.1 macrophages, and primary peritoneal macrophages from RBP4 transgenic mice were used for investigating the function of RBP4 in foam cell formation. Results: Prospective cohort studies revealed that baseline serum RBP4 level was an independent predictor for incidence of adverse cardiovascular events after adjustment for traditional risk factors. Increased RBP4 expression was observed in atherosclerotic lesions of aortic specimens from both humans and apolipoprotein E-deficient mice, and RBP4 was localized to areas rich in macrophage foam cells. RBP4 inhibition attenuated whereas overexpression accelerated atherosclerosis progression in apolipoprotein E-deficient mice. Both treatment with exogenous recombinant RBP4 and overexpression of RBP4 gene promoted macrophage-derived foam cell formation through the activation of scavenger-receptor CD36-mediated cholesterol uptake, and RBP4 transcriptionally upregulated CD36 expression in a manner dependent on jun N-terminal kinase and signal transducer and activator of transcription 1. The tyrosine kinase c-Src was identified as the upstream regulator of jun N-terminal kinase-signal transducer and activator of transcription 1-mediated CD36-dependent cholesterol uptake, and RBP4 challenge was found to alter the membrane distribution of c-Src and cause c-Src to partition into lipid-raft membrane subdomains, where the kinase was activated. Lastly, Toll-like receptor 4, but not retinol or stimulated by retinoic acid 6, mediated the inductive effects of RBP4 in macrophages. Conclusions: Inclusion of RBP4 levels in traditional models enhances the predictive ability for the incidence of atherosclerotic events. RBP4 promotes atherogenesis by inducing macrophage-derived foam cell formation.
Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study.
Authors: Michele Baccarani, H.M. Kantarjian, J.F. Apperley, J.H. Lipton, B. Druker, A. Countouriotis, R. Ezzeddine, A. Hochhaus
Journal: Blood (2006)
The TNF-Family Cytokine TL1A/Death Receptor 3 System Reduces Metabolic Activity in Chronic Lymphocytic Leukemia B Cells
Authors: Chiara Cavallini, Ornella Lovato, Anna Bertolaso, Elisa Zoratti, Cristina Tecchio, Omar Perbellini, Alberto Zamò, Giovanni Pizzolo, Maria Teresa Scupoli
Journal: Blood (2014)
Durable Responses with Bendamustine Monotherapy In Patients with Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle-Cell Lymphoma (MCL): Updated Follow-up Data From a Japanese Multicenter Phase II Study
Authors: Kuniaki Itoh, Kiyoshi Ando, Michinori Ogura, Kenichi Ishizawa, Takashi Watanabe, Naokuni Uike, Yasuhito Terui, Kensuke Usuki, Hirokazu Nagai, Nobuhiko Uoshima, Nobuko Kubota, Ken Ohmachi, Toshiki Uchida, Joji Yamamoto, Ilseung Choi, Kensei Tobinai
Journal: Blood (2010)
Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.
Authors: Yu-Tzu Tai, Audie G. Rice, Marav Leiba, Xian-Feng Li, Peter Burger, Weihua Song, Rao Prabhala, Myles Dillon, Edie Tolan, Xanling Xie, Teru Hideshima, Noopur Raje, Paul Richardson, Nihkil C. Munshi, Arnon Nagler, Herve Avet-Loiseau, Daniel E.H. Afar, Kenneth C. Anderson
Journal: Blood (2007)
Predictive Diagnostic and Prognostic Value of Platelets Microparticles (PMP), but Not of Reticulated Platelets (RP) or CD36 Expression in Essential Thrombocythaemia.
Authors: Catherine Ternisien, Marie-Pierre Moles, Aline Tanguy-Schmidt, Irene Dobo, Martine Gardembas, Franck Geneviève, Marc Zandecki, Norbert Ifrah, Mathilde Hunault-Berger
Journal: Blood (2004)
Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine,
Authors: Tomas Stopka, Nikola Curik, Pavel Burda, Karin Vargova, Vit Pospisil, Petra Vlckova, Filipp Savvulidi, Emanuel Necas, Hana Hájková, Cedrik Haskovec, Monika Belickova, Jaroslav Cermak, Marek Trneny, Anna Jonasova
Journal: Blood (2011)
Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes
Authors: Jasmijn D E de Rooij, Cristyn Branstetter, Jing Ma, Yongjin Li, Michael P Walsh, Jinjun Cheng, Askar Obulkasim, Jinjun Dang, John Easton, Lonneke J Verboon, Heather L Mulder, Martin Zimmermann, Cary Koss, Pankaj Gupta, Michael Edmonson, Michael Rusch, Joshua Yew Suang Lim, Katarina Reinhardt, Martina Pigazzi, Guangchun Song, Allen Eng Juh Yeoh, Lee-Yung Shih, Der-Cherng Liang, Stephanie Halene, Diane S Krause, Jinghui Zhang, James R Downing, Franco Locatelli, Dirk Reinhardt, Marry M van den Heuvel-Eibrink, C Michel Zwaan, Maarten Fornerod, Tanja A Gruber
Journal: Nature Genetics (2017)
A prospective assessment of polypharmacy in the palliative care setting.
Authors: Michael Joseph McNeil, Arif Kamal, Christine Ritchie, Jean Kutner, Amy Pickar Abernethy
Journal: Journal of Clinical Oncology (2014)

112 Background: The number of prescribed medications increases substantially in the last year of life aggravating the risk of polypharmacy, adverse reactions and medication non-adherence. What medications do patients with life-limiting illness take? Methods: This was a pre-specified secondary analysis of data from a prospective trial. Eligible participants were adults with a &lt;1-year prognosis taking a statin medication for primary or secondary prevention. Participants were enrolled from 15 sites, randomized to continue or discontinue statin medications, and followed for up to a year. Concomitant medications were recorded at least monthly. For participants with a primary diagnosis of cancer receiving care and with medication data available, prescribed medications were categorized according to the World Health Organization’s (WHO) ‘Guidelines for ATC Classification’ by class and sub-class. An expert panel of palliative care, oncology, geriatrics, and primary care physicians guided categorization. Descriptive statistics were calculated. Results: On average, participants (N=127) were 70 years old (SD 10) and lived 216 days (SD 123) on study; 69% had metastases, 23% had cancer without metastases, 7% had lymphoma, and 1 had leukemia. In total, 49 classes, 156 sub-classes and 283 different medications were prescribed. The five most commonly prescribed medications were: anti-hypertensives, strong opioids, laxatives, gastric protection aids, and anti-emetics. Only 1.2% of medications prescribed were chemotherapy or antineoplastics. Patients took an average of 10.7 (SD 5) number of medications at the time of enrollment and 10.0 (SD 5) medications at death or termination of the study. 31% of patients were on 15 or more medications at any time during the study. Conclusions: Polypharmacy, defined as &gt;10 medicines, is common in the last year of life for people with cancer. Patients commonly receive supportive care medications and drugs for comorbidities like hypertension; antineoplastics are rare. Thoughtful approaches to medication simplification in the palliative care setting are needed.
Incidence of Recurrence in Posterior Circulation Childhood Arterial Ischemic Stroke
Authors: Michael Y. Uohara, Lauren A. Beslow, Lori Billinghurst, Brianna M. Jones, Sudha K. Kessler, Daniel J. Licht, Rebecca N. Ichord
Journal: JAMA Neurology (2017)

<h3>Importance</h3> Childhood arterial ischemic stroke (CAIS) affects approximately 1.6 per 100 000 children per year, while stroke recurs in up to 20% of patients at 5 years. Factors determining the risk of recurrence are incompletely understood. <h3>Objective</h3> To investigate the incidence of the recurrence of CAIS in the posterior and anterior circulations to determine if the risk differs between the 2 locations. <h3>Design, Setting, and Participants</h3> A retrospective analysis of CAIS was conducted among children enrolled in a single-center prospective consecutive cohort at The Children's Hospital of Philadelphia between January 1, 2006, and January 1, 2015. Children with confirmed CAIS occurring between 29 days and 17.99 years were evaluated for inclusion. Patients were excluded if infarcts were located in both the anterior and posterior distributions or if CAIS occurred as a complication of intracranial surgery or brain tumor. <h3>Main Outcomes and Measures</h3> Stroke recurrence. <h3>Results</h3> The study population included 107 patients (75 boys [70.1%] and 32 girls [29.9%]; median age at AIS, 7.7 years [interquartile range, 3.1-13.6 years]). Sixty-one children had anterior circulation CAIS (ACAIS) and 46 had posterior circulation CAIS (PCAIS). Median follow-up was 20.9 months (interquartile range, 8.7-40.4 months). For ACAIS, recurrence-free survival was 100% at 1 month and 96% (95% CI, 85%-99%) at 1 and 3 years. For PCAIS, recurrence-free survival was 88% (95% CI, 75%-95%) at 1 month and 81% (95% CI, 66%-90%) at 1 and 3 years. The hazard ratio for recurrence after PCAIS compared with ACAIS was 6.4 (95% CI, 1.4-29.8;<i>P</i> = .02) in univariable analysis and 5.3 (95% CI, 1.1-26.4;<i>P</i> = .04) after adjusting for sex and cervical dissection. <h3>Conclusions and Relevance</h3> We identified a subgroup of patients that comprise more than 80% of recurrences of CAIS. Three years after incident stroke, 19% of children with PCAIS had a recurrence compared with 4% of patients with ACAIS. Different mechanisms of stroke may account for this difference. Children with PCAIS may warrant increased monitoring. This study highlights the necessity for further research focused on recurrence prevention.
Large measles epidemic in the Netherlands, May 2013 to March 2014: changing epidemiology
Authors: Tom Woudenberg, Rob S. van Binnendijk, Elisabeth A. M. Sanders, Jacco Wallinga, Hester E. de Melker, Wilhelmina L. M. Ruijs, Susan J. M. Hahné
Journal: Eurosurveillance (2017)

Since the early 1990s, the Netherlands has experienced several large measles epidemics, in 1992-94, 1999-2000 and in 2013-14. These outbreaks mainly affected orthodox Protestants, a geographically clustered population with overall lower measles-mumps-rubella first dose (MMR-1) vaccination coverage (60%) than the rest of the country (> 95%). In the 2013-14 epidemic described here, which occurred between 27 May 2013 and 12 March 2014, 2,700 cases were reported. Several control measures were implemented including MMR vaccination for 6-14-month-olds and recommendations to reduce the risk in healthcare workers. The vast majority of reported cases were unvaccinated (94%, n = 2,539), mostly for religious reasons (84%, n = 2,135). The median age in the epidemic was 10 years, 4 years older than in the previous epidemic in 1999-2000. A likely explanation is that the inter-epidemic interval before the 2013-2014 epidemic was longer than the interval before the 1999-2000 epidemic. The size of the unvaccinated orthodox Protestant community is insufficient to allow endemic transmission of measles in the Netherlands. However, large epidemics are expected in the future, which is likely to interfere with measles elimination in the Netherlands and elsewhere.
Clofarabine in Children with Refractory/Relapsed Acute Leukemia: Results of 2 Phase II Open Label Studies.
Authors: Sima Jeha, Bassem Razzouk, Paul Gaynon, Michael Rytting, Richard Kadota, Susan Rheingold, Lori Luchtman-Jones, Robert Arceci, Peter Steinherz
Journal: Blood (2006)
Deciphering the routes of invasion of <i>Drosophila suzukii</i> by means of ABC random forest
Authors: Antoine Fraimout, Vincent Debat, Simon Fellous, Ruth A. Hufbauer, Julien Foucaud, Pierre Pudlo, Jean-Michel Marin, Donald K. Price, Julien Cattel, Xiao Chen, Marindia Deprá, Pierre François Duyck, Christelle Guedot, Marc Kenis, Masahito T. Kimura, Gregory Loeb, Anne Loiseau, Isabel Martinez-Sañudo, Marta Pascual, Maxi Polihronakis Richmond, Peter Shearer, Nadia Singh, Koichiro Tamura, Anne Xuéreb, Jinping Zhang, Arnaud Estoup
Journal: Molecular Biology and Evolution (2017)

Deciphering invasion routes from molecular data is crucial to understanding biological invasions, including identifying bottlenecks in population size and admixture among distinct populations. Here, we unravel the invasion routes of the invasive pest Drosophila suzukii using a multi-locus microsatellite dataset (25 loci on 23 worldwide sampling locations). To do this, we use approximate Bayesian computation (ABC), which has improved the reconstruction of invasion routes, but can be computationally expensive. We use our study to illustrate the use of a new, more efficient, ABC method, ABC random forest (ABC-RF) and compare it to a standard ABC method (ABC-LDA). We find that Japan emerges as the most probable source of the earliest recorded invasion into Hawaii. Southeast China and Hawaii together are the most probable sources of populations in western North America, which then in turn served as sources for those in eastern North America. European populations are genetically more homogeneous than North American populations, and their most probable source is northeast China, with evidence of limited gene flow from the eastern US as well. All introduced populations passed through bottlenecks, and analyses reveal five distinct admixture events. These findings can inform hypotheses concerning how this species evolved between different and independent source and invasive populations. Methodological comparisons indicate that ABC-RF and ABC-LDA show concordant results if ABC-LDA is based on a large number of simulated datasets but that ABC-RF out-performs ABC-LDA when using a comparable and more manageable number of simulated datasets, especially when analyzing complex introduction scenarios.
Splenic Marginal-Zone Lymphoma: One or More Entities? A Histological, Immunohistochemical and Molecular Study of 41 Cases.
Authors: Theodora Papadaki, Kostas Stamatopoulos, Chrysoula Belessi, Evi Pouliou, Aikaterini Parasi, Nikolaos Laoutaris, Athanasios Fassas, Achilles Anagnostopoulos, Dimitra Anagnostou
Journal: Blood (2005)
Comprehensive Textbook of Psychiatry/III
Authors: H. Keith Fischer
Journal: JAMA (1982)

Eclectic, comprehensive, multiauthored (more than 236 contributors, representing more than 73 academic and clinical centers), multidisciplinary (physicians, psychiatrists, psychologists, social scientists, and others), in 57 chapters with multiple topic subdivisions, this tremendous and scholarly effort considers a majority of the psychic, biological, social, and human aspects that are the academic "territory" of modern psychiatry. The reader who masters much of this will breeze past the national boards and, later, the American Board examinations. Furthermore, he will be thinking about employing<i>DSM-III</i>in his psychiatric work. The editors of these volumes state that as "psychiatry is currently in a state of rapid development and change, commitment to any one approach would be unwise." However, in the preface to the second edition, we were admonished that "A veneration for change gives rise to galloping faddism in intellectual life," and that all "must be presented in a comprehensive psychiatric text, even at the
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
Authors: James Brophy
Journal: Annals of Internal Medicine (2017)

Source Citation Tang H, Fang Z, Wang T, et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol. 2016;118:1774-80. 27666177
Non-Cycling Cells From Acute Myeloid Leukemia Patients Harbor the FLT3-ITD Mutation and Are Insensitive to TKI258, a Potent FLT3-Directed Inhibitor, in Vitro.
Authors: Caroline L Alvares, Tino Schenk, Sanna Hulkki, Toon Min, Gowri Vijayaraghavan, Yeung Jenny, David Gonzalez, Eric So, Mel Greaves, Ian Titley, Kerol Bartolovic, Gareth Morgan
Journal: Blood (2009)
Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium
Authors: Yoshihiro Inamoto, Corey S. Cutler, Xiaoyu Chai, Mukta Arora, Paul J. Martin, Joseph Pidala, Jeanne Palmer, Steven Z. Pavletic, Madan H. Jagasia, David Jacobsohn, Paul A. Carpenter, Mary E.D. Flowers, Nandita Khera, Georgia B. Vogelsang, Daniel J. Weisdorf, Barry Storer, Stephanie J. Lee
Journal: Blood (2011)
Results of the Interim Analysis of the “HUSOM” Trial: Hungarian Study of Maintenance After Rituximab Pretreatment, A Multicentre, Phase III, Open-Label Study Evaluating the Benefit of a Long-Term MabThera (rituximab) Maintenance Therapy in Patients with Advance Follicular Lymphoma After Induction of Response (CR(u) or PR) with a MabThera (rituximab)-Containing First Line Regimen
Authors: Tamas J. Schneider, Andras Rosta, Hajna Losonczy, Gaspar Radvanyi, Gyorgy Ujj, Arpad Illes, János Jakucs, Zita Borbenyi
Journal: Blood (2011)
Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients.
Authors: Franck Emmanuel Nicolini, Wei Zhou, Giovanni Martinelli, Michael J. Mauro, Andreas Hochhaus, Jing Su, Jane Apperley, Charles Chuah, Inge Dufva, Dong-Wook Kim, Francis J. Giles, Senaka Peter, Jorge Cortes
Journal: Blood (2009)
Does salvage radiation therapy (SRT) change the biology of recurrent prostate cancer (PCa) based on PSA doubling times (PSADT)? Results from the SEARCH database.
Authors: Roberto Lodeiro Muller, Joseph C. Presti, William J Aronson, Martha K. Terris, Christopher J Kane, Christopher L Amling, Stephen J. Freedland
Journal: Journal of Clinical Oncology (2012)

203 Background: SRT offers a second opportunity for PCa control after biochemical recurrence in men treated with radical prostatectomy. Although some retrospective data suggest an overall survival benefit, we hypothesized that in men with radio-resistant tumors, SRT may indeed promote transformation to a more aggressive cancer due to radiation-induced mutations. To test this, we used PSADT as a surrogate for cancer aggressiveness and compared PSADT before and after SRT in men who failed SRT. Methods: Of 288 men who underwent SRT in the Shared Equal Access Regional Cancer Hospital (SEARCH) database since 1988, we detected 78 with SRT failure defined as PSA ≥ 0.2 ng/mL above the post-SRT nadir. Of these, 44 had PSADT available before and after SRT, which was compared using Wilcoxon’s paired test with men serving as their own controls. We also tested predictors of PSADT change using multivariable logistic regression. Results: There were no differences in PSADT before and after SRT (10.6 vs. 12.2 months; P=0.85). However, in some individual cases large changes were observed. Only seminal vesicle invasion showed a trend towards an association with a shorter post-SRT PSADT relative to the pre-SRT PSADT (P=0.067). Conclusions: Overall, the PSADT after and before SRT were statistically similar suggesting that after SRT failure, PCa does not emerge with more aggressive biologic features. Further studies are needed to identify predictors and the clinical relevance of individual PSADT changes noted in our study. (Note: Authors R. L. Muller and S. J. Freedland received support from DoD Award Number W81XWH-10-1-0155).
Toward the Ideal Ratio of Patients to Intensivists
Authors: Elizabeth M. Viglianti, Theodore J. Iwashyna
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels
Authors: Magdalena Winiarska, Jacek Bil, Kamil Bojarczuk, Dominika Nowis, Malgorzata Wanczyk, Michal Dwojak, Grzegorz Basak, Tomasz Stoklosa, Jakub Golab
Journal: Blood (2011)
Correlation of JAK2 Mutation and PRV-1 and WT1 Transcript Amount in Myeloproliferative Disorders.
Authors: Anna Serra, Sonia Carturan, Enrico Gottardi, Francesca Arruga, Francesca Messa, Paola Sterpone, Ilaria Defilippi, Valentina Rosso, Renata Catalano, Giovanni Martinelli, Francesco Iuliano, Giuseppe Saglio, Daniela Cilloni
Journal: Blood (2005)
Circulating CD52 and CD20 Levels Predict for Progression and Survival in Patients with CLL Treated with Fludarabine (F), Cyclophosphamide (C), and Rituximab (FCR).
Authors: Gheath Alatrash, Michael J. Keating, Susan O’Brien, Xuemei Wang, Taghi Manshouri, Stefan Faderl, Alessadra Ferrajoli, Hagop M. Kantarjian, Susan Lerner, William G. Wierda
Journal: Blood (2006)
Expression Level, Tissue Distribution Pattern and Prognostic Impact of Vascular Endothelial Growth Factor (VEGF) and Its Receptors Flt-1 and KDR in Different Subtypes of Non-Hodgkin Lymphoma (NHL).
Authors: Judit M. Jørgensen, Flemming B. Sørensen, Knud Bendix, Johan L. Nielsen, Anette Funder, Tapio Tainola, Annette B. Sørensen, Francesco d’Amore
Journal: Blood (2005)
Publishing data on avoidable deaths will transform hospital safety, says Hunt
Authors: Abi Rimmer
Journal: BMJ (2017)

A requirement for all NHS trusts and foundation trusts to publish data on avoidable deaths and harms will transform patient safety, England’s health secretary has said.

Speaking at a Westminster Health Forum conference in London on 26 January, Jeremy Hunt referred to plans, announced last year in a package of measures aimed at improving patient safety,1 that would require the publication of information on avoidable deaths and serious incidents from 31 March.

“From this year, every hospital will be publishing their …
Target cell-restricted apoptosis induction of acute myeloid leukemia (AML) cells by a SCFV : sTRAIL fusion protein with specificity for human CD33
Authors: B. ten Cate, Edwin Bremer, Douwe Samplonius, Theo Bijma, M. Schwemmlein, G. H. Fey, Wijnand Helfrich
Journal: Annals of Oncology (2008)
Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura.
Authors: Tadeusz Robak, Abdulgabar Salama, Lidia Kovaleva, Yaroslava I. Vyhovska, Simon Davies, Maria G. Mazzucconi, Othmar Zenker
Journal: Blood (2007)